Heart failure associated with thiazolidinediones doesn't reduce survivalBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.335.7622.692-b (Published 04 October 2007) Cite this as: BMJ 2007;335:692
A meta-analysis of seven randomised trials has confirmed that rosiglitazone and pioglitazone increase the risk of heart failure in patients with type 2 diabetes (relative risk 1.72, 95% CI 1.21 to 2.42)⇑. Fluid retention is the most likely cause, say the authors. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial